

Technical Appendix

Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region

Yang Liu^{1,2*}, Frank Sandmann^{1,2,3}, Rosanna C. Barnard^{1,2}, Carl A.B. Pearson^{1,2}, CMMID COVID-19 Working Group, Roberta Pastore⁴, Richard Pebody⁴, Stefan Flasche^{1,2}, Mark Jit^{1,2}

1 Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom

2 Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine London, United Kingdom

3 Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom

4 World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark

* Corresponding author: yang.liu@lshtm.ac.uk

CMMID COVID-19 Working Group Members:

Akira Endo, Gwenan M Knight, Joel Hellewell, Matthew Quaife, Oliver Brady, Rachael Pung, Yalda Jafari, Sam Abbott, Adam J Kucharski, Sebastian Funk, Rosalind M Eggo, W John Edmunds, Amy Gimma, Billy J Quilty, Samuel Clifford, James D Munday, Nikos I Bosse, Hamish P Gibbs, Nicholas G. Davies, Timothy W Russell, Christopher I Jarvis, Alicia Rosello, Kiesha Prem, Graham Medley, Simon R Procter, C Julian Villabona-Arenas, Damien C Tully, Katherine E. Atkins, Sophie R Meakin, Rachel Lowe, Kaja Abbas, Kathleen O'Reilly, Mihaly Koltai, William Waites, David Hodgson, Emilie Finch, Ciara V McCarthy, Paul Mee, Lloyd A C Chapman, Fiona Yueqian Sun, Stéphane Hué, Kerry LM Wong

Table of Contents

1. Details on Model Input & Assumptions	4
Table S1. Inputs and assumptions	4
1.1 Age pyramid in the WHO European Region	8
Figure S1. Population age pyramid by country	8
Table S2. Country names and their corresponding World Bank country code	12
1.2. Comorbidity-adjusted life expectancy, comorbidity- and quality-adjusted life expectancy, and discounted life expectancy	13
1.3. QALY associated with COVID-19 morbidity	13
1.4. GDP per capita used in the human capital approach	13
2. Projecting human contacts	14
2.1. Linking stringency indices to community mobility	14
Table S3. Covariates table for the general additive model (GAM) used in mobility projection (projection stage)	14
2.2. Projecting stringency indices	16
Table S4. Stringency indices on at the end of the observation window (i.e., 22 Feb 2021) ...	16
Figure S2. Stringency indices by country after incorporating the assumption on mobility recovery	17
Table S5. Missingness in community mobility reports and stringency indices	18
2.3. Projected population contacts	19
Figure S3. Projected multipliers of daily contacts before December 2022 in the <i>work</i> setting	19
Figure S4. Projected multipliers of daily contacts before December 2022 in the <i>school</i> setting	20
Figure S5. Projected multipliers of daily contacts before December 2022 in the <i>others</i> setting	21
3. Impact and Health Economic Metrics	23
Figure S8. Comorbidity adjusted life expectancy by age and by country	24
Figure S9. Gross Domestic Production per capita (GDPpc) in the WHO European Region	25
4. Additional results from the fitting process	26
Figure S10. Fitted infection introduction dates in the WHO European Region	26
Figure S11. Fitted basic reproduction numbers in the WHO European Region	27
5. Proportions of countries and populations by optimal vaccine prioritization strategies	28
Table S6. Proportions of countries with specific optimal vaccine prioritization strategies	29
Table S7. Proportions of populations with specific optimal vaccine prioritization strategies	31
6. [Sensitivity analysis] Longer waning period for vaccine-induced immunity	32

Figure S12. Optimal vaccine prioritisation strategies under different rollout scenarios and decision-making metrics using a longer vaccine waning period	32
7. Results of ordinal logistic regression exercise	33
Figure S13. Coefficients and their corresponding 90% and 95% confidence interval in the ordinal logistic regression model.	33
8. [Sensitivity analysis] Underreporting.....	34
Figure S14. Optimal vaccine prioritisation strategies under different roll-out scenarios and decision-making metrics considering underreporting	34
9. [Sensitivity analysis] Different decision time frames	35
Figure S15. Optimal vaccine prioritisation strategies under different roll-out scenarios when decision-making metrics were summarised over different decision-making time frames.....	35
10. Vaccinating adolescents.....	36
Table S8. Counts of cases where a policy is ranked first in terms of optimising health and economic benefits (including ties).....	36
11. Country-specific vaccine-prioritisation strategies by different vaccine profiles	37
Figure S16. Optimal vaccine prioritisation strategies for different vaccine characteristics under R1 and R4.....	38

1. Details on Model Input & Assumptions

Known Parameters based on Existing Knowledge				
Index	Variable		Values	Source
1	Age-specific susceptibility		0.38 - 0.88	Davies et al. ¹
2	Age-specific clinical progression rates		0.21 - 0.70	Davies et al. ¹
3	Age-specific infection fatality rates		5e-6 - 0.13	Levin et al. ²
4	Age- and country-specific within-population contact pattern		Country-specific	Prem et al. ¹
5	Country-specific population age structures		Country-specific	United Nations ³ , see also 1.1
5	Relationship between mobility and population contact pattern		Defined by linear and nonlinear functions for the <i>workplace</i> and <i>other</i> settings, respectively.	Davies et al. ⁴ by fitting to UK data.
6	CovidM	Latent period	\sim gamma ($\mu = 2.5, k = 2.5$)	Pearson et al. ⁵ Davies et al. ⁴ Davies et al. ⁶ Bi et al. ⁷ Liu et al. ⁸ Linton et al. ⁹ Nishiura et al. ¹⁰
		Duration of preclinical infectiousness	\sim gamma ($\mu = 1.5, k = 4$)	
		Duration of clinical infectiousness	\sim gamma ($\mu = 3.5, k = 4$)	
		Duration of subclinical infectiousness	\sim gamma ($\mu = 5, k = 4$)	Assumed
		Mean duration of immunity from infection	3 years	Hall et al. ¹¹

Table S1. Inputs and assumptions

Caption: The variable index numbers correspond to their numberings in Figure 1 of the main text.

Fitting Stage - input		
Index	Variable	Source
1	Country-level daily COVID-19 Mortality (including 7-day rolling average)	Roser et al. ¹² Human Rights Watch ¹³ on change in mortality case definition in Kyrgyzstan/ Kazakhstan
2	Observed country-specific community mobility	Google LLC. ¹⁴
3	COVID-19 Government Response Stringency Index and Government Response Tracker by country	Hale et al. ¹⁵

Table S1. Inputs and assumptions (Continued)

Projection Stage - input and assumptions				
Index	Variable		Values	Source
2	Vaccine characteristics	Vaccine protection duration	Baseline = 52 weeks Sensitivity analysis: 3 years	Assumed
		Infection blocking efficacy	Baseline = 0.95, varied between 0 and 0.95	
		Disease blocking efficacy	Baseline = 0.95, varied between 0.5 and 0.95	
		Vaccine roll-out scenarios	0.03 by mid-2021 and 0.2 by end of 2021, relatively slow roll-out may start after March 2021	Gavi, the vaccine alliance ¹⁶ , World Health Organisation ^{17,18}
		Maximum willingness to receive vaccination	0.7 for those between 20-59 and 0.9 for those above 90	Wouter et al. ¹⁹ Robinson et al. ²⁰ UK Government ²¹
3	Impact and health economic metrics	Country-specific comorbidity Adjusted Life Expectancy	Age-specific	See 1.2
		Mean QALY associated with COVID-19 morbidity	0.0307	See 1.3
		Median QALD associated with AEFI	1	Oliver et al. ²²
		Probability of adverse events following immunisation	50%	Pfizer and BioNTech ²³ by summing roughly summing
		Country-specific GDP per capita	Country specific	See 1.4
4	Projected mobility changes			GAM Model estimated Association between mobility and contact is

			based on Davies et al. ⁴
--	--	--	-------------------------------------

Table S1. Inputs and assumptions (Continued)

1.1 Age pyramid in the WHO European Region



Figure S1. Population age pyramid by country.

Data source: United Nations.³

Caption: Countries are labelled using their three-digit World Bank country codes.



Figure S1. Population age pyramid by country (continued).



Figure S1. Population age pyramid by country (continued).

Country Name	World Bank Country Code	Country Name	World Bank Country Code
Albania	ALB	Lithuania	LTU
Andorra	AND	Luxembourg	LUX
Armenia	ARM	Malta	MLT
Austria	AUT	Monaco	MCO
Azerbaijan	AZE	Montenegro	MNE
Belarus	BLR	Netherlands	NLD
Belgium	BEL	Norway	NOR
Bosnia & Herzegovina	BIH	Poland	POL
Bulgaria	BGR	Portugal	PRT
Croatia	HRV	Moldova	MDA
Cyprus	CYP	Romania	ROU
Czechia	CZE	Russia	RUS
Denmark	DNK	San Marino	SMR
Estonia	EST	Serbia	SRB
Finland	FIN	Slovakia	SVK
France	FRA	Slovenia	SVN
Georgia	GEO	Spain	ESP

Germany	DEU	Sweden	SWE
Greece	GRC	Switzerland	CHE
Hungary	HUN	Tajikistan	TJK
Iceland	ISL	North Macedonia	MKD
Ireland	IRL	Turkey	TUR
Israel	ISR	Turkmenistan	TKM
Italy	ITA	Ukraine	UKR
Kazakhstan	KAZ	United Kingdom	GBR
Kyrgyzstan	KGZ	Uzbekistan	UZB
Latvia	LVA		

Table S2. Country names and their corresponding World Bank country code.

1.2. Comorbidity-adjusted life expectancy, comorbidity- and quality-adjusted life expectancy, and discounted life expectancy

Data on life expectancies for each country in the WHO European Region were taken from the website of WHO.²⁴ We adjusted the life expectancies for higher risks of death due to comorbidities in those who die from COVID-19 using a recently proposed method and assuming an increased risk of 50%.²⁵ We also adjusted for health-related quality of life (HRQoL) by age using EQ-5D-3L population norms from the seven countries in Europe with a time-trade off value set available (i.e., Denmark, France, Germany, Italy, Netherlands, Spain, UK),²⁶ which indicates the potential loss of health-related quality of life (HRQoL) due to death per country (as deaths are based on country-specific estimates). Lastly, we also accounted for time preferences using a discount rate of 3.0% for future years.²⁷

1.3. QALY associated with COVID-19 morbidity

For morbidity, we assumed for each non-hospitalised case a QALY loss equivalent to symptomatic episodes of pandemic influenza-like illness.²⁸ Furthermore, we assumed that 10% of cases are hospitalised (based on raw data of hospitalisations to cases), losing 0.0201 QALYs for more than 2 months post-discharge.²⁹ Of the hospitalised cases, 50% were assumed to survive treatment in intensive-care units,³⁰ with an estimated longer-term impact of ICU survivors of 0.15 QALYs.^{31,32} Another 10% of non-hospitalised cases were assumed to suffer from post-acute symptoms (long COVID),³³ for whom we assumed a similar impact comparable to ICU survivors of 0.15 QALYs lost. In total, each symptomatic case is thus assigned a health loss equivalent to 0.0307 QALYs.

1.4. GDP per capita used in the human capital approach

For the human capital approach, we used the annual GDP per capita in international dollars (intl\$) in 2019 (or 2018 if unavailable) from the World Bank, converted by purchasing power parity (PPP).³⁴ In the absence of these data for Andorra and Monaco, we used their GDP per capita in current US\$ (without PPP conversion) from 2019 and 2018, respectively. With the GDP being a country-level productivity measure, combined with the country-specific life expectancies we derive an estimate of the economic losses per country (Figure S4) to add dimension to the health impact.

2. Projecting human contacts

2.1. Linking stringency indices to community mobility

We projected human mobility after March 2021 and before December 2022 (during which observation is not yet available) using a general additive model:

Mobility \sim day of week + (1 | country) + setting * day of week + mobility setting * month of year + stringency index

In which:

Symbol	Values	Notes
day of week	Nominal categorical values 1-7	To capture within week variability. Work-related variability, for example, vary tremendously depending on the day of week
1 country	Country code	To capture country-specific random effects
setting	Type of mobility	Type of mobility, one of “retail”, “transit”, “grocery”, and “work”.
setting * day of week	The interaction term between the type of mobility and day of week	To capture the interaction between type of mobility and day of the week.
setting * month of year	The interaction term between the type of mobility and month of year	To capture variable specific mobility seasonality. This has similar problems with using day of year as a predictor - 2020 has not fully elapsed yet so we aren’t sure what happens in Jan or Dec. In this study, we assume Dec to be similar to Nov, and Jan to be similar to Feb.
stringency index [^]	Government stringency index describing the intensity of COVID-19 related non-pharmaceutical interventions	To capture the large decrease in early 2020. Without adjusting for the stringency index, the early year mobility for 2021 and 2020 may be artificially pulled lower.

Table S3. Covariates table for the general additive model (GAM) used in mobility projection (projection stage)

Caption: Based on COVID-19 related non-pharmaceutical interventions recorded in Oxford COVID-19 Government Response Tracker, the stringency index represented the extent of containment and closure policies and public health information campaigns on the country level.¹⁵ The value of the stringency index ranges between 0 and 100, with 0 indicating the least stringent conditions, and 100

the most stringent conditions. We extracted stringency index data on 5 Mar 2021, on which complete records for our countries of interest are available before 22 Feb 2021.

2.2. Projecting stringency indices

Countries	Min	1st Quarter	Median	3rd Quarter	Max
All available (n = 50)	22	54	61	71	88
Countries with fitted models (n = 38)	28	56	68	72	88

Table S4. Stringency indices on at the end of the observation window (i.e., 22 Feb 2021)

We assume over one year from 22 Feb 2021, as vaccines roll out, stringency indices gradually recover towards pre-pandemic levels. However, due to long-term behaviour and policy changes, we expect that stringency indices will never fully return to 0 in the time frame of this study. Thus, we assume stringency indices will return to 10 over 365 days, regardless of their positions on 22 Feb 2021, following a sigmoid function. After 22 Feb 2022, the stringency indices would stay at 10 to reflect any long-term changes COVID-19 policies have on human behaviours. We impute the mobility for countries without mobility data by taking an average of the geographic neighbours.




Figure S2. Stringency indices by country after incorporating the assumption on mobility recovery.

Caption: Dark blue – empirical observations; green – transition phase; red – post-pandemic re-stabilised phase.

Countries	Number of Countries with Community Mobility Report	Number of Countries with Stringency Indices
All (n = 53)	42	50
Countries with fitted models (n = 38)	35	36

Table S5. Missingness in community mobility reports and stringency indices.

Of all countries we fitted, Albania (ALB), Armenia (ARM), and Azerbaijan (AZE) do not appear in community mobility reports; Armenia (ARM) and North Macedonia (MKD) cannot be found in the stringency index database.

2.3. Projected population contacts




Figure S3. Projected multipliers of daily contacts before December 2022 in the *work* setting

Caption: Projected multipliers of baseline contact matrices capture the changes in population contact intensity. These multipliers were calculated using projected stringency indices, projected community mobility, and the relationship between daily contacts and community mobility defined by Davies et al.⁴ using UK data. Colors represent: coral = pre-pandemic baseline; dark yellow = imputed data for countries where community mobility data is not available; green = empirical observation; pink = transition phase between pandemic and post-pandemic phases; blue = post-pandemic phase.




Figure S4. Projected multipliers of daily contacts before December 2022 in the *school* setting.

Caption: Projected multipliers of baseline contact matrices captured the changes in population contact intensity. Colors represent: coral = pre-pandemic baseline; dark yellow = imputed data for countries where community mobility data is not available; green = empirical observation; pink = transition phase between pandemic and post-pandemic phases; blue = post-pandemic phase. During the period where empirical observation was available, the contacts in the *school* setting were modulated by the “school closure” variable (i.e. C1_school_closing) in the Oxford COVID-19 government response tracker. The variable C1_school_closing is ordinal: when C1_school_closing reached the highest value (i.e. 3, require closing all levels), the multiplier was set to 0 to indicate no school contacts; when C1_school_closing reached the lowest value (i.e. 0, require closing all levels), the multiplier was set to 1 to indicate *school*-based contacts were similar to pre-pandemic levels; when C1_school_closing was set to levels in between, the multiplier was assumed to be 0.5 to indicate an intermediate level of *school*-based contact intensity. During the transition between pandemic and post-pandemic phases and the post-pandemic phases, contacts in the *school* setting were only driven by the summer and winter holidays. The timing of summer and winter holidays varies in the European Union.³⁵ Here, we broadly assume summer holidays to go for two months between July and August, and winter holidays to go for 3 weeks between mid-December to the first week of January. During school holidays, *school*-based contacts were set to 0.




Figure S5. Projected multipliers of daily contacts before December 2022 in the *others* setting.

Caption: Projected multipliers of baseline contact matrices capture the changes in population contact intensity. These multipliers were calculated using projected stringency indices, projected community mobility, and the relationship between daily contacts and community mobility defined by Davies et al.⁴ using UK data. Colors represent: coral = pre-pandemic baseline; dark yellow = imputed data for countries where community mobility data is not available; green = empirical observation; pink = transition phase between pandemic and post-pandemic phases; blue = post-pandemic phase.




Figure S6. Projected multipliers of daily contacts before December 2022 in the *home* setting.

Caption: Projected multipliers of baseline contact matrices capture the changes in population contact intensity. Colors represent: coral = pre-pandemic baseline; dark yellow = imputed data for countries where community mobility data is not available; green = empirical observation; pink = transition phase between pandemic and post-pandemic phases; blue = post-pandemic phase. Home-based contacts are expected to stay constant in this study. The Google community mobility report showed increased time spent at home during the pandemic.¹⁴ We argue that this change does not affect transmission as both pandemic and pre-pandemic time and contacts at home are likely above the time and contacts required for transmission.³⁶

3. Impact and Health Economic Metrics

The three health-economic metrics can then be calculated using the following equations:

- (1) Comorbidity-adjusted life expectancy (cLE) loss =
 age-specific COVID-19 mortality *
 age-specific comorbidity-adjusted life expectancy (adjLE)

- (2) Comorbidity- and quality-adjusted life year (cQALY) loss =
 age-specific discounted comorbidity- and quality- adjusted life
 expectancy (adjQALEdisc) *
 age-specific COVID-19 mortality +
 mean QALY loss associated with COVID-19 morbidity *
 COVID-19 symptomatic cases +
 mean QALY loss associated with AEFI * Number of vaccines deployed *
 AEFI occurrence probability

- (3) Human Capital (HC) loss =
 total discounted life expectancy (LEdisc) * GDP per capita




Figure S7. Numeric differences between crude life expectancy and comorbidity adjusted life expectancy (adjLE), discounted life expectancy (LEdisc) and discounted comorbidity- and quality-adjusted life expectancy (adjQALEdisc).




Figure S8. Comorbidity adjusted life expectancy by age and by country.




Figure S9. Gross Domestic Production per capita (GDPpc) in the WHO European Region

4. Additional results from the fitting process




Figure S10. Fitted infection introduction dates in the WHO European Region.

Caption: The underlying fitting structure involves two varying parameters - infection introduction date and the basic reproduction number. Country shapefiles are downloaded from Eurostat GISCO.³⁷ Cross-hatched regions indicate countries where model fit was not achieved due to data availability and quality issues discussed in the main text.




Figure S11. Fitted basic reproduction numbers in the WHO European Region.

Caption: The underlying fitting structure involves two varying parameters - infection introduction date and the basic reproduction number. Country shapefiles are downloaded from Eurostat GISCO.³⁷ Cross-hatched regions indicate countries where model fit was not achieved due to data availability and quality issues discussed in the main text.

5. Proportions of countries and populations by optimal vaccine prioritization strategies.

Roll-out Scenario	Decision-making Metrics	Proportion of countries with fitted models with this optimal vaccine prioritisation strategy (n = 38)			
		V+	V20	V60	V75
R1	Deaths	0.0263	0.1842	0.1316	0.6579
R1	Cases	0.0000	1.0000	0.0000	0.0000
R1	Adj. Life Expectancy	0.0263	0.3684	0.5526	0.0526
R1	Quality Adj. Life Years	0.0526	0.3947	0.5000	0.0526
R1	Human Capital	0.0263	0.3421	0.6053	0.0263
R2	Deaths	0.2105	0.3158	0.2368	0.2368
R2	Cases	0.1053	0.8947	0.0000	0.0000
R2	Quality Adj. Life Years	0.2895	0.5263	0.1842	0.0000
R2	Adj. Life Expectancy	0.2632	0.5789	0.1579	0.0000
R2	Human Capital	0.2632	0.4737	0.2632	0.0000
R3	Deaths	0.3421	0.1579	0.4474	0.0526
R3	Cases	0.4474	0.0526	0.2895	0.2105
R3	Adj. Life Expectancy	0.3684	0.1579	0.3421	0.1316

R3	Quality Adj. Life Years	0.3947	0.0789	0.4211	0.1053
R3	Human Capital	0.3684	0.1579	0.3684	0.1053
R4	Deaths	0.4474	0.5000	0.0263	0.0263
R4	Cases	0.4737	0.1316	0.1316	0.2632
R4	Adj. Life Expectancy	0.4737	0.4474	0.0789	0.0000
R4	Quality Adj. Life Years	0.5000	0.4211	0.0789	0.0000
R4	Human Capital	0.4737	0.4737	0.0526	0.0000

Table S6. Proportions of countries with specific optimal vaccine prioritization strategies.

Caption: The denominator for these proportions is 38, the number of countries within the WHO European Region without data availability or sparsity issues.

Roll-out Scenario	Decision-making Metrics	Proportion of population in countries with fitted models with this optimal vaccine prioritisation strategy (n = 848,407)			
		V+	V20	V60	V75
R1	Deaths	0.0126	0.1521	0.0499	0.7854
R1	Cases	0	1	0	0
R1	Adj. Life Expectancy	0.0126	0.2454	0.7362	0.0057
R1	Quality Adj. Life Years	0.132	0.2581	0.6042	0.0057
R1	Human Capital	0.0126	0.2331	0.752	0.0022
R2	Deaths	0.1721	0.1169	0.316	0.395
R2	Cases	0.134	0.866	0	0
R2	Quality Adj. Life Years	0.2419	0.4352	0.323	0
R2	Adj. Life Expectancy	0.2467	0.5017	0.2517	0
R2	Human Capital	0.2405	0.3988	0.3607	0
R3	Deaths	0.474	0.1328	0.2911	0.1021
R3	Cases	0.5175	0.0213	0.2189	0.2423
R3	Adj. Life Expectancy	0.4788	0.1328	0.2404	0.148

R3	Quality Adj. Life Years	0.4948	0.032	0.3455	0.1278
R3	Human Capital	0.4788	0.1328	0.2606	0.1278
R4	Deaths	0.2541	0.7401	0.0022	0.0035
R4	Cases	0.2576	0.3194	0.2465	0.1764
R4	Adj. Life Expectancy	0.2606	0.6568	0.0827	0
R4	Quality Adj. Life Years	0.2641	0.6465	0.0895	0
R4	Human Capital	0.2606	0.7337	0.0057	0

Table S7. Proportions of populations with specific optimal vaccine prioritization strategies.

Caption: The denominator for these proportions is 848,407, the populations of countries within the WHO European Region without data availability or sparsity issues.

6. [Sensitivity analysis] Longer waning period for vaccine-induced immunity




Figure S12. Optimal vaccine prioritisation strategies under different rollout scenarios and decision-making metrics using a longer vaccine waning period

Caption: The underlying fitting structure involves two varying parameters - infection introduction dates and the basic reproduction numbers. Vaccine-induced immunity is assumed to wane exponentially over 3 years (as opposed to 52 weeks, presented in the main text). Main panel - Optimal strategies across the WHO European Region identified using decision metrics of cumulative COVID-19 deaths, cases, and losses in adjusted life expectancy (cLE), quality-adjusted life-years (cQALY), and human capital (HC). Inner panel - Comparing the use of a given prioritisation strategy across the WHO European Region against the use of country-specific optimal prioritisation strategies (indicated with black points). Sidebars - The proportion of total population for which each prioritisation strategy is optimal. Country shapefiles are downloaded from Eurostat GISCO;³⁷ countries marked by crosshatch patterns are those that were not included in the fitting stage.

7. Results of ordinal logistic regression exercise




Figure S13. Coefficients and their corresponding 90% and 95% confidence interval in the ordinal logistic regression model.

Caption: The sole dependent variable is the optimal vaccine prioritisation strategy identified. There are five groups of independent variables: (1) age-specific contact patterns, (2) vaccine rollout scenarios, (3) population size, (4) proportion of older adults, and (5) the proportion of individuals no longer susceptible to SARS-CoV-2 by 01 January 2021. Not all variables within each group were presented here - those with Pearson's correlation larger than 0.4 were eliminated to avoid multicollinearity issues.

8. [Sensitivity analysis] Underreporting




Figure S14. Optimal vaccine prioritisation strategies under different roll-out scenarios and decision-making metrics considering underreporting

Caption: The underlying fitting structure involves three varying parameters - infection introduction dates, the basic reproduction numbers, and an underreporting probability. Main panel - Optimal strategies across the WHO European Region identified using decision metrics of cumulative COVID-19 deaths, cases, and losses in adjusted life expectancy (cLE), quality-adjusted life-years (cQALY), and human capital (HC). Inner panel - Comparing the use of a given prioritisation strategy across the WHO European Region against the use of country-specific optimal prioritisation strategies (indicated with black points). Sidebars - The proportion of total population for which each prioritisation strategy is optimal. Country shapefiles are downloaded from Eurostat GISCO;³⁷ countries marked by crosshatch patterns are those that were not included in the fitting stage.

9. [Sensitivity analysis] Different decision time frames




Figure S15. Optimal vaccine prioritisation strategies under different roll-out scenarios when decision-making metrics were summarised over different decision-making time frames.

Caption: The right columns in each panel is another way to visualise the results already presented in the main text, Figure 4 - the results presented in these columns are each decision-making metric summarised between 01 Jan 2021 and 31 Dec 2022. Noticeably, the vaccination programs elapsed for different durations under different rollout scenarios. For R1 and R2, the vaccination campaigns were assumed to start on 01 March 2021; for R3 and R4, the vaccination campaigns were assumed to start on 01 January 2021. The rest represents results summarised over decision time frames. Among them, “6m”, “12m” and “18m” represents decision time frames ending on the 6th, 12th, and 18th months after the start of vaccination campaigns. In these columns, vaccine program lengths were the same across roll-out strategies.

10. Vaccinating adolescents

We did not include those younger than 20 years of age in any baseline analysis as most vaccine products currently available are not authorised for such age groups in most countries in the WHO European Region at the time of this study. As results from clinical trials conducted among adolescents emerge, some vaccines are now authorised for use in those between 12 and 15 years of age in a small number of countries.³⁸ We thus expanded our analysis to include adolescents using the fastest vaccine roll-out scenario explored (i.e. R4) as it is the only one involving substantial vaccine surplus. We only expanded using V60 and V75 as the last groups vaccinated were younger adults, with whom it may make sense to potentially include adolescents. We found that vaccinating adolescents would bring additional health and economic benefits and that vaccinating adolescents simultaneously with younger adults was more beneficial than vaccinating them after the maximum uptake level among younger adults have been reached.

Roll-out Strategy	Policy	Deaths	Cases	Adj. Life Expectancy	Quality Adj. Life Years	Human Capital
R4	V60	9	20	12	11	10
R4	V60a	17	5	10	16	18
R4	V60b	12	13	10	11	10
R4	V75	11	13	10	11	11
R4	V75a	27	25	28	27	27
R4	V75b	11	13	10	11	11

Table S8. Counts of cases where a policy is ranked first in terms of optimising health and economic benefits (including ties)

Caption: The denominator for these proportions is 38, the number of countries within the WHO European Region without data availability or sparsity issues. In the expansion (a), adolescents were vaccinated with the last group in the baseline strategy; in the expansion (b), adolescents were vaccinated after the last group in the baseline strategy had reached their maximum uptake level.

11. Country-specific vaccine-prioritisation strategies by different vaccine profiles



Figure S16. Optimal vaccine prioritisation strategies for different vaccine characteristics under R1 and R4.

Caption: Optimal strategy for each country and vaccine profile while minimising mortality, morbidity, adjusted life expectancy (cLE), quality-adjusted life-years (cQALY), or human capital (HC) losses for 38 countries in the WHO European Region with fitted models. Countries are arranged in the order of the expected proportion of the population no longer susceptible to SARS-CoV-2 on 01 Jan 2021 (descending).

References

- 1 Davies N, Klepac P, Liu Y, Prem K, Jit M, Eggo R. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nature Medicine* 2020; **26**: 1205+.
- 2 Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol* 2020; **35**: 1123–38.
- 3 United Nations Department of Economic and Social Affairs. 2019 Revision of World Population Prospects. <https://population.un.org/wpp/> (accessed Nov 2, 2020).
- 4 Davies NG, Barnard RC, Jarvis CI, *et al.* Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. *The Lancet Infectious Diseases* 2021; **21**: 482–92.
- 5 Pearson CAB, Bozzani F, Procter SR, *et al.* Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan. *medRxiv* 2021; : 2021.02.24.21252338.
- 6 Davies N, Kucharski A, Eggo R, Gimma A, Edmunds W, COV C for the MM of ID. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. *Lancet Public Health* 2020; **5**: e375–85.
- 7 Bi Q, Wu Y, Mei S, *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet Infectious Diseases* 2020; **20**: 911–9.
- 8 Liu Y, Centre for Mathematical Modelling of Infectious Diseases nCoV, Funk S, Flasche S. The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019. *Wellcome Open Research* 2020; **5**: 58.
- 9 Linton NM, Kobayashi T, Yang Y, *et al.* Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *Journal of Clinical Medicine* 2020; **9**: 538.
- 10 Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. *International Journal of Infectious Diseases* 2020; **93**: 284–6.
- 11 Hall V, Foulkes S, Charlett A, *et al.* Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. *medRxiv* 2021; : 2021.01.13.21249642.
- 12 Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus (COVID-19) Deaths - Statistics and Research. *Our World in Data* <https://ourworldindata.org/covid-deaths> (accessed April 11, 2021).
- 13 Kyrgyzstan/Kazakhstan: New Rules for Tallying Covid-19 Data. Human Rights Watch. 2020; published online July 21. <https://www.hrw.org/news/2020/07/21/kyrgyzstan/kazakhstan-new-rules-tallying-covid-19-data> (accessed April 9, 2021).
- 14 Google Inc. COVID-19 Community Mobility Report. COVID-19 Community Mobility Report. 2020. <https://www.google.com/covid19/mobility?hl=en> (accessed May 18, 2020).
- 15 Hale T, Angrist N, Goldszmidt R, *et al.* A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nature Human Behaviour* 2021; : 1–10.

- 16 Gavi, the Vaccine Alliance. The COVAX Facility: Interim Distribution Forecast. 2021 <https://www.gavi.org/sites/default/files/covid/covax/COVAX-Interim-Distribution-Forecast.pdf> (accessed March 26, 2021).
- 17 World Health Organization. COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021. World Health Organization. 2020; published online Dec 18. <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021> (accessed April 11, 2021).
- 18 COVAX reaches over 100 economies, 42 days after first international delivery. World Health Organization. <https://www.who.int/news/item/08-04-2021-covax-reaches-over-100-economies-42-days-after-first-international-delivery> (accessed April 11, 2021).
- 19 Wouters OJ, Shadlen KC, Salcher-Konrad M, *et al.* Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *The Lancet* 2021; **397**: 1023–34.
- 20 Robinson E, Jones A, Lesser I, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples. *Vaccine* 2021; **39**: 2024–34.
- 21 Department of Health and Social Care (UK). UK COVID-19 vaccine uptake plan. <https://www.gov.uk/government/publications/covid-19-vaccination-uptake-plan/uk-covid-19-vaccine-uptake-plan> (accessed April 18, 2021).
- 22 Oliver SE, Gargano JW, Marin M, *et al.* The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United States, December 2020. *Morbidity and Mortality Weekly Report* 2020; **69**: 1922.
- 23 Pfizer-BioNTech. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020. US Food and Drug Administration, 2020.
- 24 World Health Organization. Global Health Observatory data repository | Life tables by WHO region - Europe. World Health Organization. <https://apps.who.int/gho/data/view.main.LIFEEUR?lang=en> (accessed April 21, 2021).
- 25 Briggs AH, Goldstein DA, Kirwin E, *et al.* Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. *Health Economics* 2021; **30**: 699–707.
- 26 Szende A, Janssen B, Cabases J, editors. Self-Reported Population Health: An International Perspective based on EQ-5D. Dordrecht: Springer Netherlands, 2014 DOI:10.1007/978-94-007-7596-1.
- 27 World Health Organization. WHO guide for standardization of economic evaluations of immunisation programmes. <https://apps.who.int/iris/bitstream/handle/10665/329389/WHO-IVB-19.10-eng.pdf> (accessed April 21, 2021).
- 28 Hoek AJ van, Underwood A, Jit M, Miller E, Edmunds WJ. The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study. *PLOS ONE* 2011; **6**: e17030.
- 29 Halpin SJ, McIvor C, Whyatt G, *et al.* Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *Journal of Medical Virology* 2021; **93**: 1013–22.

- 30 Bennett S, Tafuro J, Mayer J, *et al.* Clinical features and outcomes of adults with coronavirus disease 2019: A systematic review and pooled analysis of the literature. *International Journal of Clinical Practice* 2021; **75**: e13725.
- 31 Cuthbertson BH, Roughton S, Jenkinson D, MacLennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. *Crit Care* 2010; **14**: R6.
- 32 Griffiths J, Hatch RA, Bishop J, *et al.* An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. *Crit Care* 2013; **17**: R100.
- 33 Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ* 2020; **370**: m3026.
- 34 The World Bank. GDP per capita, PPP (current international \$). <https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD> (accessed April 21, 2021).
- 35 Education, Audiovisual and Culture Executive Agency. The organisation of school time in Europe: primary and general secondary education: 2019/20. LU: Publications Office, 2019 <https://data.europa.eu/doi/10.2797/678694> (accessed April 26, 2021).
- 36 US CDC. Public Health Guidance for Community-Related Exposure. Centers for Disease Control and Prevention. 2020; published online Feb 11. <https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html> (accessed April 26, 2021).
- 37 Eurostat. GISCO data distribution API - Countries 2020. <https://gisco-services.ec.europa.eu/distribution/v1/countries-2020.html> (accessed April 12, 2021).
- 38 FDA Office of the Commissioner. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. FDA, 2021 <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use> (accessed June 15, 2021).